Center for world class biotechnology
As a biotech region, Berlin ranks among the leaders in Europe.
Biotechnology is an important driver of innovation in the Berlin-Brandenburg health region. The industry is experiencing steady growth and a high start-up dynamic. The great potential of the location, especially in the field of gene and cell therapy, is demonstrated, for example, by the promising spin-offs from the research centers in the capital region over the past three years and the planned project by Bayer and the Charité, the Center for Gene and Cell Therapies.
Many of the biotech companies were founded by local universities and research institutions. The particular focus here is so-called "red biotechnology," which involves the application of biotechnology to pharmaceuticals and the practice of medicine. Of the approx. 300 biotech companies with about 8,200 employees in the region, almost 80% work in biomedicine. They are developing innovative therapeutic and diagnostic methods for the treatment of cancer, cardiovascular disease, and diabetes, and benefit from the region's strengths in science and research and its infrastructure for clinical trials.
These local conditions and level of expertise make the capital region attractive for global pharmaceutical companies that can develop and produce innovative products here.
Why Berlin?
„As a cosmopolitan metropolis, Berlin offers opportunities to be at the cutting edge. With our Berlin roots as a Charité spin-off, we have been contributing to innovative technologies in the pharmaceutical industry for almost 30 years now. We believe that this cosmopolitan, dynamic and diverse environment provides the best breeding ground not only to build on long success stories, but also to write new chapters.“
